Back to Trades
Total Value
$11.6K
Filing Date
Jul 20, 2026
1 transactions
Trade Summary
On Jul 16, 2026 through Jul 20, 2026, Crutcher Patrick J, Director, reported $11.6K of Jasper Therapeutics, Inc. (JSPR) across 1 transactions. The filing covers company securities and reflects balanced net activity of $0. Reported prices ranged from $0.77. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- Jasper Therapeutics, Inc.
- Ticker Symbol
- JSPR
- CIK
- 0001788028
Insider Information
- Role
- Director
- Location
- REDWOOD CITY, CA
Filing Details
- Filing Date
- Jul 20, 2026
- Transaction Date
- Jul 16, 2026
- Accession Number
- 0001213900-26-079764
- Form Type
- 4
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Jul 16, 2026 | JSPR derivative | 15,000 | $0.77 | Grant/Award | $11.6K |
| Jul 20, 2026 | JSPR derivative | 888 | — | Purchase | — |
Want live alerts when Crutcher Patrick J trades again?
Download Insider Trades to track JSPR, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)The shares shall vest as follows: 25% on the one-year anniversary of the date of grant and the remaining shares shall vest in equal monthly installments over the next 36 months until fully vested, subject to continuous service through each applicable vesting date.
- (F2)On July 16, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold the referenced shares of preferred stock to the Reporting Person in a private placement, which closed on July 20, 2026.
- (F3)On the third business day following the receipt of stockholder approval of the conversion of the preferred stock, each share of preferred stock shall automatically convert into 61 shares of the Issuer's voting common stock ("Voting Common Stock"), subject to certain limitations, including that a holder of preferred stock is prohibited from converting shares of preferred stock into shares of Voting Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Voting Common Stock issued and outstanding immediately after giving effect to such conversion. The preferred stock has no expiration date.